protocol H8D-MC-EMBH PPAR Alpha (LY518674): a phase 2 dose-response study to evaluate the blood pressure-lowering effect in essential hypertension

Trial Profile

protocol H8D-MC-EMBH PPAR Alpha (LY518674): a phase 2 dose-response study to evaluate the blood pressure-lowering effect in essential hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs LY 518674 (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 May 2007 Status changed from suspended
    • 14 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top